Company Update

Transgene Biotek Limited has submitted a Compliance Certificate for the quarter ended 31st March 2025, confirming that, during the reporting period, no shares were received for transfer, sub-division, consolidation, renewal, exchange, or endorsement of calls/allotment monies.

This reflects a stable status regarding equity share transactions, which may indicate operational consistency.

While the compliance is a standard procedure, the lack of share activities could suggest limited trading interest among shareholders at this time.

Investors might view this as a neutral impact on liquidity and trading activity.